Profile data is unavailable for this security.
About the company
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
- Revenue in USD (TTM)334.51m
- Net income in USD71.52m
- Incorporated2008
- Employees895.00
- LocationMiMedx Group Inc1775 W Oak Commons Court, NeMARIETTA 30062United StatesUSA
- Phone+1 (770) 651-9100
- Fax+1 (678) 384-6720
- Websitehttps://mimedx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 881.75m | 24.00 | -- | 3.93 | -- | 88,174.68 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Pharvaris NV | 0.00 | -115.15m | 896.05m | 82.00 | -- | 2.30 | -- | -- | -2.57 | -2.57 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -75.45m | 898.43m | 49.00 | -- | 2.30 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 914.60m | 140.00 | -- | 3.45 | -- | 24.57 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 932.52m | 85.00 | -- | 1.64 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| MiMedx Group Inc | 334.51m | 71.52m | 1.00bn | 895.00 | 18.02 | 6.43 | 12.58 | 3.00 | 0.3767 | 0.3393 | 2.15 | 1.06 | 1.72 | 2.82 | 6.58 | 373,754.20 | 41.80 | -4.14 | 53.13 | -5.90 | 83.50 | 83.61 | 24.36 | -2.70 | 2.71 | 9.00 | 0.111 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.00bn | 284.00 | -- | -- | -- | 24.14 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.03bn | 267.00 | -- | -- | -- | 2.49 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.05bn | 46.00 | -- | 3.30 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 1.06bn | 593.00 | -- | 18.75 | -- | 7.56 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.09bn | 173.00 | -- | 2.17 | -- | 12.21 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.09bn | 171.00 | -- | 1.80 | -- | 53.47 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.12bn | 280.00 | -- | 1.83 | -- | 6.93 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Sana Biotechnology Inc | 0.00 | -308.61m | 1.13bn | 328.00 | -- | 3.00 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Data as of Jul 05 2024. Currency figures normalised to MiMedx Group Inc's reporting currency: US Dollar USD
24.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.93m | 5.37% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.73m | 3.88% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.94m | 3.35% |
| Paradigm Capital Management, Inc.as of 31 Mar 2024 | 3.91m | 2.65% |
| Trigran Investments, Inc.as of 31 Mar 2024 | 3.26m | 2.21% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.62m | 1.78% |
| Cannell Capital LLCas of 31 Mar 2024 | 2.43m | 1.65% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.81m | 1.23% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 1.76m | 1.19% |
| RBC Global Asset Management (US), Inc.as of 31 Mar 2024 | 1.26m | 0.85% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
